OSIR Profile
Osiris Therapeutics, Inc. (OSIR) was a biotechnology company that developed and marketed regenerative medicine products to treat a variety of medical conditions. The company was acquired by Smith & Nephew plc in 2019 and is no longer publicly traded.
Before the acquisition, OSIR reported a net loss of $17.6 million for the nine months ended September 30, 2018. The company had cash and cash equivalents of $43.1 million as of September 30, 2018.
Osiris Therapeutics' growth strategy focused on advancing its pipeline of regenerative medicine products and obtaining regulatory approval for its products. The company's focus on developing innovative therapies for unmet medical needs enabled it to establish a strong presence in the biotechnology industry.
Investing in biotechnology companies like Osiris Therapeutics carries market risks, including the risk of market volatility, clinical trial setbacks, regulatory hurdles, and competition from other biotechnology providers. Investors should carefully consider these risks before investing in OSIR (now part of Smith & Nephew) and consult with a financial advisor to determine if it is an appropriate investment for their portfolio. They should also review the company's public disclosures and financial statements to gain a better understanding of its financial performance and risks.
|
